Literature DB >> 17218018

PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease.

Daniel L Alkon1, Miao-Kun Sun, Thomas J Nelson.   

Abstract

There is strong evidence that protein kinase C (PKC) isozyme signaling pathways are causally involved in associative memory storage. Other observations have indicated that PKC signaling pathways regulate important molecular events in the neurodegenerative pathophysiology of Alzheimer's disease (AD), which is a progressive dementia that is characterized by loss of recent memory. This parallel involvement of PKC signaling in both memory and neurodegeneration indicates a common basis for the origins of both the symptoms and the pathology of AD. Here, we discuss this conceptual framework as a basis for an autopsy-validated peripheral biomarker--and for AD drug design targeting drugs (bryostatin and bryologs) that activate PKC isozymes--that has already demonstrated significant promise for treating both AD neurodegeneration and its symptomatic memory loss.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218018     DOI: 10.1016/j.tips.2006.12.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  66 in total

1.  Total synthesis of bryostatin 1.

Authors:  Gary E Keck; Yam B Poudel; Thomas J Cummins; Arnab Rudra; Jonathan A Covel
Journal:  J Am Chem Soc       Date:  2010-12-22       Impact factor: 15.419

2.  Fluorescent-responsive synthetic C1b domains of protein kinase Cδ as reporters of specific high-affinity ligand binding.

Authors:  Nami Ohashi; Wataru Nomura; Tetsuo Narumi; Nancy E Lewin; Kyoko Itotani; Peter M Blumberg; Hirokazu Tamamura
Journal:  Bioconjug Chem       Date:  2010-12-22       Impact factor: 4.774

3.  Happy birthday protein kinase C: past, present and future of a superfamily.

Authors:  Fiorenzo Battaini; Daria Mochly-Rosen
Journal:  Pharmacol Res       Date:  2007-05-18       Impact factor: 7.658

4.  Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.

Authors:  Gary E Keck; Yam B Poudel; Dennie S Welch; Matthew B Kraft; Anh P Truong; Jeffrey C Stephens; Noemi Kedei; Nancy E Lewin; Peter M Blumberg
Journal:  Org Lett       Date:  2009-02-05       Impact factor: 6.005

5.  Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke.

Authors:  Zhenjun Tan; Ryan C Turner; Rachel L Leon; Xinlan Li; Jarin Hongpaisan; Wen Zheng; Aric F Logsdon; Zachary J Naser; Daniel L Alkon; Charles L Rosen; Jason D Huber
Journal:  Stroke       Date:  2013-10-30       Impact factor: 7.914

6.  Total synthesis of bryostatin 16 using a Pd-catalyzed diyne coupling as macrocyclization method and synthesis of C20-epi-bryostatin 7 as a potent anticancer agent.

Authors:  Barry M Trost; Guangbin Dong
Journal:  J Am Chem Soc       Date:  2010-11-02       Impact factor: 15.419

7.  Convergent assembly of highly potent analogues of bryostatin 1 via pyran annulation: bryostatin look-alikes that mimic phorbol ester function.

Authors:  Gary E Keck; Matthew B Kraft; Anh P Truong; Wei Li; Carina C Sanchez; Noemi Kedei; Nancy E Lewin; Peter M Blumberg
Journal:  J Am Chem Soc       Date:  2008-05-02       Impact factor: 15.419

8.  Evaluation of systemic administration of Boswellia papyrifera extracts on spatial memory retention in male rats.

Authors:  Ali Mahmoudi; Ali Hosseini-Sharifabad; Hamid R Monsef-Esfahani; Ali R Yazdinejad; Mahnaz Khanavi; Ali Roghani; Cordian Beyer; Mohammad Sharifzadeh
Journal:  J Nat Med       Date:  2011-04-11       Impact factor: 2.343

9.  In Vivo Chimeric Alzheimer's Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons.

Authors:  Ramsey Najm; Kelly A Zalocusky; Misha Zilberter; Seo Yeon Yoon; Yanxia Hao; Nicole Koutsodendris; Maxine Nelson; Antara Rao; Alice Taubes; Emily A Jones; Yadong Huang
Journal:  Cell Rep       Date:  2020-07-28       Impact factor: 9.423

10.  A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.

Authors:  Tapan K Khan; Thomas J Nelson; Vishal A Verma; Paul A Wender; Daniel L Alkon
Journal:  Neurobiol Dis       Date:  2009-02-20       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.